172 results on '"Kesselheim, Aaron S."'
Search Results
2. Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020
3. Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies
4. Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA
5. Physician and Device Manufacturer Tort Liability for Remote Patient Monitoring Devices
6. The cost of drug patent expiration date errors
7. Biologic patent challenges under the America Invents Act
8. Independent Advice on Drug Approvals: an Investigation of EMA Practices
9. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma
10. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework
11. Rates and costs of drug testing practices for private payors in the outpatient setting in the United States, 2015–2019
12. Regulating Laboratory Tests: What Framework Would Best Support Safety and Validity?
13. Global cooperation and early access—clinical outcomes matter
14. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis
15. Patient perspectives on evidence supporting drug safety and effectiveness: "What does it mean for me?".
16. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.
17. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study.
18. Trust in the Food and Drug Administration: A National Survey Study.
19. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
20. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition
21. Identifying therapeutic alternatives in Medicare drug price negotiation: The case of etanercept
22. How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians
23. Delivery Device Patents on GLP-1 Receptor Agonists
24. Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa
25. Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care
26. Association between changes in prices and out‐of‐pocket costs for brand‐name clinician‐administered drugs
27. Physicians’ Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey
28. Why Some Patients Overpay for Specialty Generic Drugs
29. Biosimilar Uptake In The US: Patient And Prescriber Factors
30. Federal Trade Commission Actions on Prescription Drugs, 2000-2022.
31. Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
32. Medicare Negotiation's Drug Reformulation Problem.
33. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
34. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
35. Federal Enforcement of Pharmaceutical Fraud under the False Claims Act, 2006–2022.
36. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
37. Spending on Targeted Therapies for Duchenne Muscular Dystrophy.
38. Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.
39. Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.
40. Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis.
41. Preserving Timely Generic Drug Competition with Legislation on "Skinny Labeling".
42. Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections.
43. Drug Repurposing Via the Best Pharmaceuticals for Children Act.
44. The Origins of "Confidential Commercial Information" at the FDA.
45. The FDA in the Crosshairs—Science, Politics, and Abortion.
46. Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.
47. Leah Z. Rand, Daniel P. Carpenter, Aaron S. Kesselheim, Anushka Bhaskar, Jonathan J. Darrow, and William B. Feldman Reply.
48. Federal Oversight of Laboratory-Developed Tests.
49. Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone–Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
50. Quantifying Research and Development Expenditures in the Drug Industry.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.